API ADAD Colombia , NCT01998841: A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort |
|
|
| Completed | 2 | 252 | RoW | Crenezumab, MABT5102A, Placebo | Genentech, Inc., Banner Alzheimer's Institute, National Institute on Aging (NIA) | Alzheimer's Disease | 03/22 | 08/23 | | |
